Navigation Links
American Heart Association Late-Breaking Clinical Trial Report: New Reversible Antiplatelet Drug no More Effective Than Irreversible One in PCI
Date:11/15/2009

pproved antiplatelet drug that binds irreversibly to platelets.

Those in the cangrelor group got 30 micrograms (mcg) of cangrelor per kilogram (kg) of body weight intravenously, followed by a 4 mcg/kg/per minute infusion for at least two hours. At the end of the procedure, they received a 600 milligram (mg) dose of clopidogrel.

Patients in the clopidogrel group received a standard 600 mg loading dose immediately prior to their PCI. Following the procedure all patients received a maintenance dose of 75 mg of clopidogrel and aspirin therapy (75 mg to 325 mg/day) for at least 30 days thereafter.

Patients received all other anti-clotting therapies according to care standards at their treatment site.

"There was no statistically significant difference in the primary composite endpoint (death, heart attack and ischemic revascularization at 48 hours), which affected 7.5 percent of the cangrelor group vs. 7.1 percent for the clopidogrel group," Harrington said. But, in formal non-inferiority 1160 testing, cangrelor appeared to maintain more than 60 percent of the benefit of 600 (mg) clopidogrel over placebo.

When looked at together with data from the companion trial, researchers also found a reduction in acute stent thrombosis, which are blood clots within the metal mesh stent implanted during PCI to help hold the vessel open. The two treatment groups were well balanced in baseline characteristics. It was noted that there was more minor bleeding associated with cangrelor.

This is the first study to use a 600-mg dose (instead of 300-mg dose) of clopidogrel as the comparison drug and to compare that dose to cangrelor. Cangrelor is the first drug in a class of intravenous P2Y12 receptor antagonists. It provides immediate and intense inhibition of platelet clotting, but, as opposed to clopidogrel, this effect can be reversed.

"With its fast onset and reversibility, cangrelor holds the potent
'/>"/>

SOURCE American Heart Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Viron to Present Data from Phase II Trial at American Heart Association Conference
2. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
3. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
4. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
5. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
6. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
7. American Oriental Bioengineering Announces September Investor Conferences Participation
8. American Scientific Resources To Be Exclusive Seller of Worlds Only FDA Approved Home Needle Destruction Device
9. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
10. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
11. American Oriental Bioengineering Announces Change in Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... San Diego, California (PRWEB) January 22, 2015 ... R Promotional Offer to their comprehensive portfolio of ... Offer allows customers to purchase a Centrifuge 5424/5424 R ... Pipette Bundle of either Eppendorf Research plus or Eppendorf ...
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... for cells and tissues  ("BioLife" or the "Company"), today ... Stockholders on May 4, 2015 (the "Annual Meeting"). ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... SHANGHAI, June 29 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE:, ... by China,s Ministry of Commerce,to the list of Top Ten ... Second Annual China International Service Outsourcing,Cooperation Conference, held in Nanjing ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) , ...
... ... to attend conference ,Wed. September 30-Friday, October 2, 2009. , ... Portland, Maine (PRWEB) June 26, 2009 -- ... Production and Storage 2009," an International conference bringing together hydrogen producers, developers and ...
... REYKJAVIK, Iceland, June 26 deCODE genetics,(Nasdaq: DCGN ... the Nasdaq,Hearing and Listing Review Council that the listing of ... Market effective from the,opening of trading on Monday, June 29. ... , The reinstatement follows the Listing ...
Cached Biology Technology:WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise 2Industry Leaders Will Gather to Discuss the Future of the "Hydrogen Economy" in Washington DC 2deCODE Reinstated to Nasdaq Global Market 2deCODE Reinstated to Nasdaq Global Market 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced today ... to confirm its adherence to current U.S. Food and ... conduct regulated smart device and smart phone application trials ... quality. "HITLAB is determined to improve global ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... offering. One major trend emerging in ... in technology, it is important to upgrade biometric solutions ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... of undergraduate students from Stevens Institute of Technology was ... by the International Society for Pharmaceutical Engineering (ISPE). ... students and was held last month at the ISPE ... poster, titled "Evaluation of a Posterior Criciate Ligament Tensioning ...
... is good for you, at least if you are a ... Oncology Center have shown that in healthy cells, a bundled ... storehouse, in its proper place. Understanding this cap,s influence on ... to the diagnosis and treatment of diseases such as cancer, ...
... identification of substances involved in the Jekyll-and-Hyde transformation that ... bleaching." Their study appears in ACS, Environmental Science ... and colleagues note that bleaching already has destroyed up ... scientists are searching for ways to slow or stop ...
Cached Biology News:A cell's 'cap' of bundled fibers could yield clues to disease 2
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Taq DNA polymerase, 10,000U...
... DNA Polymerase is the most thoroughly characterized ... testimony to its overall utility and efficacy. ... ideal for PCR applications. , It ... ,, AmpliTaq DNA Polymerase is a ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
Biology Products: